My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 232

    1.

    Repaglinide administration improves brachial reactivity in type 2 diabetic patients.

    Manzella D, Grella R, Abbatecola AM, Paolisso G.

    Diabetes Care. 2005 Feb;28(2):366-71.PMID: 15677794 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.

    Rizzo MR, Barbieri M, Grella R, Passariello N, Paolisso G.

    Diabetes Metab. 2005 Jun;31(3 Pt 1):255-60.PMID: 16142016 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.

    Yngen M, Ostenson CG, Hjemdahl P, Wallén NH.

    Diabet Med. 2006 Feb;23(2):134-40.PMID: 16433710 [PubMed - indexed for MEDLINE]Related articles

    4.

    Chronic vitamin E administration improves brachial reactivity and increases intracellular magnesium concentration in type II diabetic patients.

    Paolisso G, Tagliamonte MR, Barbieri M, Zito GA, Gambardella A, Varricchio G, Ragno E, Varricchio M.

    J Clin Endocrinol Metab. 2000 Jan;85(1):109-15.PMID: 10634373 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.

    Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Teerlink T, Gram J, Winther K, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA.

    Eur J Endocrinol. 2008 May;158(5):631-41.PMID: 18426821 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

    Damsbo P, Clauson P, Marbury TC, Windfeld K.

    Diabetes Care. 1999 May;22(5):789-94.PMID: 10332683 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Oral amino acid administration decreases oxidative stress and improves brachial reactivity in elderly individuals.

    Manzella D, Grella R, Esposito K, Cacciapuoti F, Arciello A, Giugliano D, Paolisso G.

    Am J Hypertens. 2005 Jun;18(6):858-63.PMID: 15925748 [PubMed - indexed for MEDLINE]Related articles

    8.

    Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.

    Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR.

    Diabetes Care. 2002 Aug;25(8):1271-6.PMID: 12145220 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.

    Landgraf R, Bilo HJ, Müller PG.

    Eur J Clin Pharmacol. 1999 May;55(3):165-71.PMID: 10379630 [PubMed - indexed for MEDLINE]Related articles

    10.

    Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.

    Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group.

    Circulation. 2004 Jul 13;110(2):214-9. Epub 2004 Jun 14.PMID: 15197140 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.

    Schmitz O, Lund S, Andersen PH, Jønler M, Pørksen N.

    Diabetes Care. 2002 Feb;25(2):342-6.PMID: 11815507 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.

    Rosak C, Hofmann U, Paulwitz O.

    Diabetes Nutr Metab. 2004 Jun;17(3):137-42.PMID: 15334790 [PubMed - indexed for MEDLINE]Related articles

    13.

    Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.

    Hollingdal M, Sturis J, Gall MA, Damsbo P, Pincus S, Veldhuis JD, Pørksen N, Schmitz O, Juhl CB.

    Diabet Med. 2005 Oct;22(10):1408-13.PMID: 16176204 [PubMed - indexed for MEDLINE]Related articles

    14.

    Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.

    Owens DR, Luzio SD, Ismail I, Bayer T.

    Diabetes Care. 2000 Apr;23(4):518-23.PMID: 10857945 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.

    Martens FM, Visseren FL, de Koning EJ, Rabelink TJ.

    J Cardiovasc Pharmacol. 2005 Dec;46(6):773-8.PMID: 16306801 [PubMed - indexed for MEDLINE]Related articles

    16.

    Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.

    Abbink EJ, van der Wal PS, Sweep CG, Smits P, Tack CJ.

    Diabetes Metab Res Rev. 2004 Nov-Dec;20(6):466-71.PMID: 15386823 [PubMed - indexed for MEDLINE]Related articles

    17.

    The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.

    Reboussin DM, Goff DC Jr, Lipkin EW, Herrington DM, Summerson J, Steffes M, Crouse RJ 3rd, Jovanovic L, Feinglos MN, Probstfield JL, Banerji MA, Pettitt DJ, Williamson J.

    Diabet Med. 2004 Oct;21(10):1082-9.PMID: 15384954 [PubMed - indexed for MEDLINE]Related articles

    18.

    Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.

    Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA.

    Eur J Endocrinol. 2008 Jan;158(1):35-46.PMID: 18166815 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients.

    Tankova T, Koev D, Dakovska L, Kirilov G.

    Diabetes Res Clin Pract. 2003 Jan;59(1):43-9.PMID: 12482641 [PubMed - indexed for MEDLINE]Related articles

    20.

    A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

    Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG.

    Diabetes Care. 1998 Nov;21(11):1897-903.PMID: 9802740 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity